nach oben

Inflammopharmacology

Erschienen in:

01.06.2015 | Research Article

Effect of bisphosphonates treatment on cytokine imbalance between TH17 and Treg in osteoporosis

verfasst von: Roba M. Talaat, Asmaa Sidek, Ahmed Mosalem, Ahmed Kholief

Erschienen in: Inflammopharmacology | Ausgabe 2-3/2015

Einloggen, um Zugang zu erhalten

Abstract

Imbalance of T-helper-cell (TH) subsets (TH1/TH2/TH17) and regulatory T cells (Tregs) is suggested to contribute to the pathogenesis of osteoporosis. Broken TH17/Treg balance has been reported contributing to several inflammatory diseases. Although bisphosphonates are well-recognized inhibitors of osteoclastic activity, there is no serious examination of their effect on T cell subset (TH1/TH2/TH17/Treg) balances. Patients were categorized into 20 osteopenic and 20 osteoporotic patients treated with bisphosphonates for 1 year. We studied plasma levels of interleukins 4 (IL-4), IL-6, IL-10, IL-12, IL-17, IL-23, and interferon-gamma (IFN-γ), and transforming growth factor-beta (TGF-β) and their interrelations and correlation with osteoporosis treatment were evaluated. Treated osteoporotic patients have a significant reduction of plasma IL-6 (p < 0.05), IL-17 (p < 0.05), IL-23 (p < 0.05), and IFN-γ (p < 0.05), a significant increase in IL-4 (p < 0.05), IL-10 (p < 0.05), and TGF-β (p < 0.001), and comparable IL-12 levels as compared to controls. In conclusion, the significant reduction of Th17 cell cytokine cascade (IL-6, IL-17, and IL-23) and elevation of Treg cytokine cascade (IL-10 and TGF-β) might be considered as a very important observation about the effect of bisphosphonates on TH17/Treg imbalance in osteoporosis.

Abdelmagid SM, Barbe MF, Safadi FF (2015) Role of inflammation in the aging bones. Life Sci 123:25–34CrossRefPubMed

Baker PJ (2000) The role of immune responses in bone loss during periodontal disease. Microbes Infect 2(10):1181–1192CrossRefPubMed

Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319(6053):516–518CrossRefPubMed

Boskey AL, Spevak L, Weinstein RS (2009) Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 20:793–800CrossRefPubMedCentralPubMed

Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27:68–73CrossRefPubMed

Cantatore FP, Acquista CA, Pipitone V (1999) Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 26:2318–2323PubMed

Dong C (2006) Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 6(4):329–333CrossRefPubMed

Ducy P, Schinke T, Karsenty G (2000) The osteoblast: a sophisticated fibroblast under central surveillance. Science 289:1501–1504CrossRefPubMed

Feng X, McDonald J (2011) Disorders of bone remodeling. Annu Rev Pathol 6:121–145CrossRefPubMedCentralPubMed

Giuliani N, Girasole G, PedrazzoniM Passeri G, Gatti C, Passeri M (1995) Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res 10:S171

Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG (1983) An interleukin 1-like factor stimulates bone resorption in vitro. Nature 306(5941):378–380CrossRefPubMed

Grcević D, Katavić V, Lukić IK, Kovacić N, Lorenzo JA, Marusić A (2001) Cellular and molecular interactions between immune system and bone. Croat Med J. 42(4):384–392PubMed

Hill PA, Tumber A, Papaioannou S, Meikle MC (1998) The cellular actions of interleukin-11 on bone resorption in vitro. Endocrinology 139(4):1564–1572CrossRefPubMed

Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T et al (1990) IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145(10):3297–3303PubMed

Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141CrossRefPubMed

Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402(6759):304–309CrossRefPubMed

Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352CrossRefPubMedCentralPubMed

Miyaura C, Kusano K, Masuzawa T, Chaki O, Onoe Y, Aoyagi M, Sasaki T, Tamura T, Koishihara Y, Ohsugi Y et al (1995) Endogenous bone-resorbing factors in estrogen deficiency: cooperative effects of IL-1 and IL-6. J Bone Miner Res 10(9):1365–1373CrossRefPubMed

Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357PubMed

Nakamura M, Uehara S, Nakamura H, Udagawa N (2014) Cytokine-mediated bone resorption. Clin Calcium 24(6):837–844PubMed

Passeri G, Girasole G, Uljetti V, Guiliani N, Pedrazzoni M, Sartori L, Jilka RL, Manolagas SC (1994) Bisphosphonates inhibit IL-6 production by human osteoblastic cells MG-63. J Bone Miner Res 9(suppl):S230

Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276–1287CrossRefPubMedCentralPubMed

Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001–6007PubMed

Ro C, Cooper O (2013) Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep 11:45–51CrossRefPubMedCentralPubMed

Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289(5484):1508–1514CrossRefPubMed

Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6:345–352CrossRefPubMed

Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T (2006) Foxp3-CD25-CD4- natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8–27CrossRefPubMed

Sato K, Takayanagi H (2006) Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol 18(4):419–426CrossRefPubMed

Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203(12):2673–2682CrossRefPubMedCentralPubMed

Sato M, Nakamichi Y, Nakamura M, Sato N, Ninomiya T, Muto A, Nakamura H, Ozawa H, Iwasaki Y, Kobayashi E, Shimizu M, DeLuca HF, Takahashi N, Udagawa N (2007) New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro. Bone 40(2):293–304CrossRefPubMed

Schenk R, Eggli P, Fleisch H, Rosini S (1986) Quantitative morphometric evaluation of the inhibitory activity of new aminophosphonates on bone resorption in the rat. Calif Tissue Int 38:342–349CrossRef

Steeve K, Marc P, Sandrine T, Dominique H, Yannick F (2004) IL-6, RANKL, TNF-α/IL-1 interactions in bone resorption pathophysiology. Cytokine Growth Factor Rev 15:49–60CrossRef

Suresh E, Pazianas M, Abrahamsen B (2014) Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology 53:19–31CrossRefPubMed

Takayanagi H (2005) Inflammatory bone destruction and osteoimmunology. J Periodontal Res 40:287–293CrossRefPubMed

Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408(6812):600–605CrossRefPubMed

Talaat RM, El-Bassiouny AI, Osman AM, Yossif M, Charmy R, Al-Sherbiny MM (2007) Cytokine secretion profile associated with periportal fibrosis in S. mansoni-infected Egyptian patients. Parasitol Res 101(2):289–299CrossRefPubMed

Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504–1508CrossRefPubMed

Theill LE, Boyle WJ, Penninger JM (2002) RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795–823CrossRefPubMed

von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS (2005) Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26(34):6941–6949CrossRef

Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 24:33–63CrossRefPubMed

Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24(6):677–688CrossRefPubMed

Titel: Effect of bisphosphonates treatment on cytokine imbalance between TH17 and Treg in osteoporosis
verfasst von: Roba M. Talaat
Asmaa Sidek
Ahmed Mosalem
Ahmed Kholief
Publikationsdatum: 01.06.2015
Verlag: Springer Basel
Erschienen in: Inflammopharmacology / Ausgabe 2-3/2015
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-015-0233-4

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Effect of bisphosphonates treatment on cytokine imbalance between TH17 and Treg in osteoporosis

Abstract

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2015

Reply to: “Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives” Inflammopharmacology DOI:10.1007/s10787-014-0202-3

Mechanism of Rac1-induced amplification in gastric mucosal phospholipase Cγ2 activation in response to Helicobacter pylori: modulatory effect of ghrelin

Regulatory role of guanine nucleotide exchange factor (GEF) Dock180 phosphorylation on Tyr/Ser in mediation of gastric mucosal Rac1 activation in response to Helicobacter pylori and ghrelin

Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs

Exposure to non-steroid anti-inflammatory drugs (NSAIDs) and suppressing hydrogen sulfide synthesis leads to altered structure and impaired function of the oesophagus and oesophagogastric junction

Role of fish oil in human health and possible mechanism to reduce the inflammation